Spleen stiffness accurately tracks early and sustained portal pressure changes after transjugular intrahepatic portosystemic shunt

Table 1 Demographic and clinical characteristics of the patients evaluated for the study, n (%)

Patients characteristics	Value
Age (years)	60.2 (56.0-66.0)
Male gender	22 (56.4)
Body mass index (kg/m2)	24.1 (21.1-27.3)
Etiology of portal hypertension
HBV/HCV	9 (23.1)
PSVD	9 (23.1)
Cryptogenic	8 (20.5)
PBC	6 (15.4)
Alcohol	6 (15.4)
NASH	1 (2.6)
Child-Pugh grade
A, B, C	20 (51.3), 17 (43.6), 2 (5.1)
MELD score	8.6 (4.6-10.9)
Indication for TIPS placement
Variceal bleeding	33 (84.6)
Refractory ascites	6 (15.4)

Quantitative data were expressed as median (25%-75% quartile). HBV: Hepatitis B virus; HCV: Hepatitis C virus; PSVD: Porto-sinusoidal vascular disorder; PBC: Primary biliary cholangitis; NASH: Non-alcoholic steatohepatitis; MELD: Model of end-stage liver disease; TIPS: Transjugular intrahepatic portosystemic shunt.

Table 2 Changes in laboratory parameters before and after transjugular intrahepatic portosystemic shunt placement

Characteristics	Before TIPS (n = 39)	After TIPS (n = 39)	P value
ALT (U/L)	33.97 ± 34.05	67.79 ± 79.35	< 0.001
AST (U/L)	45.41 ± 55.65	97.77 ± 117.26	< 0.001
ALP (U/L)	113.13 ± 130.62	119.23 ± 202.33	0.261
γ-GT (U/L)	78.18 ± 116.36	73.10 ± 107.24	0.085
Serum albumin (g/L)	34.04 ± 5.10	33.08 ± 5.61	0.207
Serum total bilirubin (μmol/L)	26.31 ± 15.94	33.72 ± 21.84	0.005
Serum creatinine (μmol/L)	74.48 ± 30.78	75.03 ± 32.77	0.867
Platelets (109/L)	90.28 ± 68.96	33.97 ± 34.05	0.460
INR	1.27 ± 0.15	1.38 ± 0.24	< 0.001
PT	15.22 ± 1.60	16.93 ± 2.27	< 0.001
WBC (109/L)	4.44 ± 3.54	6.34 ± 4.25	0.001
Hemoglobin (g/L)	87.72 ± 26.66	86.18 ± 29.12	0.464

ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ALP: Alkaline phosphatase; γ-GT: Γ-glutamyl transferase; INR: International normalised ratio; PT: Prothrombin time; WBC: White blood cells; TIPS: Transjugular intrahepatic portosystemic shunt.